Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;21(2):253-261.
doi: 10.1007/s11154-020-09563-8.

Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas

Affiliations
Review

Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas

Michael Buchfelder et al. Rev Endocr Metab Disord. 2020 Jun.

Abstract

Surgery of aggressive pituitary adenomas and pituitary carcinomas is part of the interdisciplinary management of these difficult to treat tumors. Invasion, giant size and unusual, asymmetric extent of these tumors frequently require modifications or extensions of the standard approaches for transsphenoidal and transcranial surgery. Frequently, only debulking procedures can be performed. In aggressive and hormone secreting adenomas, the remission rates achieved by surgery alone are relatively poor and adjuvant medical treatments or irradiation are needed. Safe resection of as much tumor as possible and symptomatic control is aimed at, rather than remission. Many procedures are required for rapid progression of lesions or recurrences, in order to extend the survival of the patients. Metastases of pituitary carcinomas within the cranial cavity or spine can be attacked. Since they can occur anywhere in the brain or spinal canal they require the entire battery of neurosurgical approaches. Unfortunately, in this group of pituitary tumors, the complication rates are higher than in primary operations of enclosed adenomas. The respective techniques with their facilities and limitations are reviewed in this article.

Keywords: Aggressive growth; Cavernous sinus; Interdisciplinary management; Invasive adenoma; Pituitary carcinomas; Transcranial surgery; Transsphenoidal surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Rapid progression of a non-functioning pituitary adenoma in a 30-year-old female patient, as depicted on T1-weghted coronal MR images: a on presentation b delayed postoperative imaging 3 months after transsphenoidal surgery c follow-up investigation after 2 years d superimposing tumor structures onto operative field during repeat transsphenoidal surgery e delayed postoperative imaging after repeat surgery f RT-planning of residual tumor g most recent follow-up 5 years after conformal fractionated irradiation
Fig. 2
Fig. 2
Invasive growth pattern of pituitary adenomas, encasing the internal carotid artery (✸) and optic nerve (arrow) (a) or growing and destroying along the anterior skull base and medial wall of the right orbit (b + c)
Fig. 3
Fig. 3
Giant size is not a limit for tumour resection as long as there is a sufficient communication between intra- and suprasellar components (a+b). Depite of the large size, the tumor could be readily resected (c+d) as the delayed postoperative MRI shows
Fig. 4
Fig. 4
A 48-year-old female patient presented with a large and invasive adenoma and a 3rd nerve palsy of the left eye (a). After transspehnoidal debulking surgery a supraclinoidal parasellar tumour (✸) persisted (b), which latter was resected via a fronto-temporal craniotomy (c)
Fig. 5
Fig. 5
Limitations of transsphenidal tumor resection by cavernous sinus invasion: In this Knosp 4 grade tumour (a), the parasellar tumour portion could not be resected for the invasive nature of the adenoma, which has encased the intracavernous carotid artery (b)
Fig. 6
Fig. 6
Progressive cerebral metastasis at the bottom of the right lateral ventricle of a PRL-secreting pituitary carcinoma (a). A small right frontal craniotomy (b) and transventricular approach (c) was chosen to resect the metastasis (d)
Fig. 7
Fig. 7
Progressive spinal metastasis of a Proalctin-secreting pituitary adenoma. After first appearance (a) the metastasis showed a rapid progression (b). Intraoperative views (c + d) of the adherent metastasis. Despite irradiation and medical therapy with dopamine-agonists and temozolomide the spinal metastasis progressed continuously (e)

References

    1. McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P, Hubalewska-Dydejezky A, Assie G, Bach L, Batisse-Lignier M, Berinder K, Bilbao I, Bonnet F, Bresson D, Bruno O, Campdera M, Caron P, Castinetti F, Ceccato F, Chabre O, Chanson P, Christ E, Cloix L, Cortet C, Criniere L, Cuatrecasas G, Debono M, Delemer B, Desailloud R, Deutschbein T, Dusek T, Engström BE, Faustini-Fustini M, Franck S, Garcia C, Greenman Y, Gil SM, Mantovani G, Gurnell M, Heaney A, Henley D, Higham C, Hoving EW, Höybye C, Ichihara A, Jaffrain-Rea ML, Johannsson G, Jorgensen JOL, Jublanc C, Komor J, Korbonits M, Kralievic I, Larrieu-Ciron D, Lasolle H, Laws E, Losa M, Maiter D, Marcocci C, Marques OC, Mazzuco TL, Micko A, Bourcigaux N, Neggers S, Newell-Price J, Perez-Berida B, Ortiz LD, Ragnarsson O, Ragonese M, Reincke M, Sadoul JL, Shimatsu A, Syro LV, Taillandier L, Toth M, Usui T, Valkusz Z, Vila G, Whitelaw B, Zatelli MC. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265–276. doi: 10.1530/eje-17-0933. - DOI - PubMed
    1. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, _ _. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1–g24. doi: 10.1530/eje-17-0796. - DOI - PubMed
    1. Dworakowska D, Grossman AB. Aggressive and malignant pituitary tumours: state-of-the-art. Endocr Relat Cancer. 2018;25(11):R559–Rr75. doi: 10.1530/erc-18-0228. - DOI - PubMed
    1. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol. 2008;68(6):970–975. doi: 10.1111/j.1365-2265.2007.03139.x. - DOI - PubMed
    1. Buchfelder M, Schlaffer SM, Zhao Y. The optimal surgical techniques for pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101299. doi: 10.1016/j.beem.2019.101299. - DOI - PubMed

Publication types